Try
Teva Pharmaceutical Industries Limited
TEVAUnited States
71 filed reports · 920 financial concepts · 2 earnings calls · 10 media appearances
Filed reports
71 reports · Dec 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 316 guidance figures, 182 interim figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Current · 8-KSEC EDGAR | 33 | 316 | Dec 2017 to Jun 2026 |
| Quarterly · 10-QSEC EDGAR | 26 | 7,186 | Mar 2018 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 9 | 7,819 | Dec 2017 to Dec 2025 |
| Interim · 6-KSEC EDGAR | 2 | 579 | Jun 2017 to Sep 2017 |
| Annual · 20-FSEC EDGAR | 1 | 655 | Dec 2016 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 8-K | Jun 30, 2026 | Jul 29, 2026 | 14 | Open |
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Jul 29, 2026 | 569 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | Apr 29, 2026 | 14 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | Apr 29, 2026 | 401 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 3, 2026 | 1,518 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Jan 28, 2026 | 12 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 5, 2025 | 14 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 411 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Jul 30, 2025 | 253 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Jul 30, 2025 | 12 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 242 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 7, 2025 | 12 | Open |
Financial data
920 concepts · 16,555 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial849 concepts · 12,059 facts · Dec 2010 to Jun 2026
- Common stock par or stated value per share61 · Dec 2015 to Jun 2026
- Loss contingency accrual at carrying value58 · Dec 2017 to Jun 2026
- Cash and cash equivalents at carrying value56 · Dec 2014 to Jun 2026
- Accumulated other comprehensive income loss net of tax55 · Dec 2014 to Jun 2026
- Gross profit (US GAAP)55 · Dec 2014 to Jun 2026
- Revenue55 · Dec 2014 to Jun 2026
- Comprehensive income net of tax54 · Dec 2014 to Jun 2026
- Comprehensive income net of tax including portion attributable to noncontrolling interest54 · Dec 2014 to Jun 2026
- Cost of goods and services sold (US GAAP)54 · Dec 2014 to Jun 2026
- General and administrative expense (US GAAP)54 · Dec 2014 to Jun 2026
- Impairment of long lived assets held for use54 · Dec 2014 to Jun 2026
- Income tax expense benefit54 · Dec 2014 to Jun 2026
- Legal settlements and loss contingencies54 · Dec 2014 to Jun 2026
- Net income loss54 · Dec 2014 to Jun 2026
- Nonoperating income expense54 · Dec 2014 to Jun 2026
- Operating income loss54 · Dec 2014 to Jun 2026
- Other assets impairments, restructuring and other items54 · Dec 2014 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax54 · Dec 2014 to Jun 2026
- Profit loss54 · Dec 2014 to Jun 2026
- Research and development expense excluding acquired in process cost54 · Dec 2014 to Jun 2026
- Restructuring charges54 · Dec 2014 to Jun 2026
- Selling and marketing expense (US GAAP)54 · Dec 2014 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest54 · Dec 2014 to Jun 2026
- Total54 · Dec 2014 to Jun 2026
Segment32 concepts · 2,792 facts · Dec 2014 to Jun 2026
- Revenue1,438 · Dec 2014 to Jun 2026
- Operating income loss224 · Dec 2014 to Jun 2026
- Research and development expense excluding acquired in process cost170 · Dec 2014 to Jun 2026
- Selling and marketing expense (US GAAP)170 · Dec 2014 to Jun 2026
- General and administrative expense (US GAAP)150 · Dec 2016 to Jun 2026
- Gross profit (US GAAP)140 · Dec 2014 to Sep 2024
- North America131 · Dec 2016 to Jun 2026
- Goodwill106 · Dec 2016 to Jun 2026
- Operating Income79 · Dec 2015 to Mar 2026
- Goodwill foreign currency translation gain loss29 · Dec 2017 to Dec 2025
- Cost of revenue (US GAAP)24 · Dec 2022 to Jun 2026
- Goodwill impairment loss19 · Dec 2017 to Dec 2024
- Cost of goods and services sold (US GAAP)18 · Mar 2024 to Sep 2025
- Europe17 · Dec 2017 to Dec 2025
- Depreciation12 · Mar 2025 to Jun 2026
- Gross Profit8 · Jun 2016 to Sep 2017
- R&D Expense8 · Jun 2016 to Sep 2017
- Selling and Marketing Expense8 · Jun 2016 to Sep 2017
- Other Segments7 · Mar 2018 to Jun 2018
- Revenue (excluding assessed tax)5 · Jun 2020 to Sep 2023
- Licenses revenue4 · Mar 2017 to Mar 2018
- Other sales revenue net4 · Mar 2017 to Mar 2018
- Product revenue4 · Mar 2017 to Mar 2018
- Operating Segments3 · Dec 2017
Product13 concepts · 850 facts · Dec 2014 to Jun 2026
- Revenue674 · Dec 2014 to Jun 2026
- Revenue (excluding assessed tax)134 · Mar 2018 to Mar 2026
- Identifiable Ipr And D11 · Dec 2017
- Impairment of intangible assets excluding goodwill6 · Mar 2019 to Dec 2020
- Restructuring charges6 · Dec 2016 to Dec 2017
- Business combination contingent consideration arrangements change in amount of contingent consideration liability13 · Dec 2017 to Dec 2018
- Impairment of intangible assets finitelived3 · Dec 2016
- Methyl ER3 · Mar 2019 to Sep 2019
- Viread3 · Dec 2017 to Dec 2020
- Property, Plant & Equipment, Net2 · Jun 2017 to Sep 2017
- Revenue (including assessed tax)2 · Jun 2018
- Teva And Subsidiaries2 · Dec 2016 to Dec 2017
- Other asset impairment charges1 · Dec 2015
Geography19 concepts · 538 facts · Dec 2015 to Jun 2026
- Goodwill foreign currency translation gain loss130 · Dec 2018 to Jun 2026
- Revenue104 · Dec 2016 to Jun 2026
- Property, Plant & Equipment, Net88 · Dec 2015 to Dec 2025
- Goodwill67 · Dec 2017 to Jun 2026
- Europe49 · Dec 2018 to Dec 2025
- Goodwill impairment loss35 · Jun 2018 to Dec 2024
- United States21 · Mar 2019 to Mar 2026
- Goodwill acquired during period8 · Mar 2022 to Dec 2022
- Goodwill written off related to sale of business unit8 · Dec 2018 to Dec 2019
- Distribution fees4 · Mar 2017 to Mar 2018
- Licenses revenue4 · Mar 2017 to Mar 2018
- Operating Segments4 · Dec 2017
- Product revenue4 · Mar 2017 to Mar 2018
- Impairment of long lived assets held for use3 · Mar 2018 to Dec 2025
- International Markets3 · Dec 2019
- Loss contingency damages paid value3 · Mar 2018 to Sep 2018
- Impairment of long lived assets to be disposed of1 · Mar 2018
- Loss contingency damages sought value1 · Sep 2022
- Tangible asset impairment charges1 · Dec 2018
Guidance7 concepts · 316 facts · Feb 2018 to Jul 2026
- Revenue Guidance66 · Feb 2018 to Jul 2026
- Effective Tax Rate Guidance60 · Aug 2018 to Jul 2026
- EPS (Diluted) Guidance52 · Feb 2018 to Jul 2026
- Free Cash Flow Guidance50 · Feb 2018 to Jul 2026
- Operating Income Guidance46 · Feb 2018 to Jul 2026
- Capital Expenditures Guidance34 · Feb 2019 to Jul 2026
- Operating Margin Guidance8 · Nov 2025 to Jul 2026
Segments
4,180 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments22 members · 2,734 facts
- International Markets727 · Dec 2016 to Jun 2026
- Europe571 · Dec 2016 to Jun 2026
- North America548 · Dec 2016 to Dec 2023
- United States269 · Dec 2022 to Jun 2026
- Other Activities223 · Dec 2016 to Jun 2026
- All Other Segments60 · Dec 2014 to Jun 2026
- Generics55 · Dec 2014 to Dec 2017
- Specialty54 · Dec 2014 to Dec 2017
- Corporate38 · Dec 2015 to Mar 2026
- Europe segment35 · Dec 2017 to Jun 2026
- International markets35 · Dec 2017 to Jun 2026
- Segments and other activities33 · Dec 2015 to Sep 2024
- North america segment24 · Dec 2017 to Sep 2023
- Generics18 · Jun 2016 to Dec 2017
- Specialty18 · Jun 2016 to Dec 2017
- Growth Market10 · Mar 2017 to Mar 2018
- Other activities6 · Jun 2018 to Sep 2023
- All other segments6 · Dec 2016 to Sep 2018
- Medis1 · Dec 2018
- Rimsa1 · Mar 2018
- Medis1 · Dec 2018
- Rimsa1 · Mar 2018
Product or servicesrt:ProductOrServiceAxis32 members · 703 facts
- License147 · Dec 2016 to Jun 2026
- Product147 · Dec 2016 to Jun 2026
- Distribution Service122 · Dec 2016 to Jun 2026
- Product And Service Other113 · Dec 2016 to Jun 2026
- Ajovy21 · Mar 2019 to Mar 2026
- Anda21 · Mar 2018 to Sep 2025
- Austedo20 · Mar 2018 to Sep 2025
- Copaxone19 · Mar 2019 to Mar 2026
- Other products18 · Sep 2019 to Mar 2026
- Generics medicians17 · Mar 2019 to Sep 2024
- Pro air8 · Mar 2018 to Sep 2021
- Lenalidomide Product6 · Mar 2019 to Dec 2020
- Qvar6 · Mar 2018 to Sep 2020
- COPAXONE4 · Mar 2018 to Jun 2019
- Generics Medicians4 · Mar 2018 to Jun 2019
- Other Products4 · Mar 2018 to Jun 2019
- Methyl Er3 · Mar 2019 to Sep 2019
- Anda2 · Jun 2018 to Jun 2019
- Austedo2 · Jun 2018 to Jun 2019
- Distribution2 · Mar 2018 to Mar 2019
- Pro Air2 · Jun 2018 to Jun 2019
- QVAR2 · Jun 2018 to Jun 2019
- Distribution2 · Jun 2019 to Sep 2019
- Treanda And Bendeka2 · Jun 2018 to Jun 2019
- Distribution service2 · Jun 2020 to Mar 2026
- Ajovy1 · Jun 2019
- Atripala1 · Dec 2020
- Expenses Related To Bendeka1 · Dec 2018
- Tiruvada1 · Dec 2020
- Product and service other1 · Jun 2018
- Product1 · Jun 2018
- Viread1 · Dec 2017
Statement geographicalsrt:StatementGeographicalAxis20 members · 491 facts
- Europe117 · Dec 2016 to Jun 2026
- North America94 · Dec 2016 to Dec 2025
- International Markets68 · Dec 2017 to Jun 2026
- US56 · Mar 2019 to Jun 2026
- Other countries29 · Dec 2017 to Jun 2026
- Other Countries24 · Dec 2017 to Jun 2026
- Us21 · Dec 2018 to Jun 2026
- Cz9 · Dec 2017 to Dec 2025
- Hr9 · Dec 2017 to Dec 2025
- Il9 · Dec 2017 to Dec 2025
- Europe9 · Dec 2017 to Dec 2025
- International markets9 · Dec 2017 to Dec 2025
- De8 · Dec 2017 to Dec 2025
- Hu7 · Dec 2017 to Dec 2023
- North america7 · Dec 2017 to Dec 2023
- Ie7 · Dec 2019 to Dec 2025
- Jp3 · Dec 2017 to Dec 2019
- IN3 · Mar 2018 to Dec 2018
- IL1 · Sep 2018
- MX1 · Jun 2018
Product or serviceus-gaap:ProductOrServiceAxis27 members · 147 facts
- Branded40 · Dec 2014 to Dec 2017
- Generics40 · Dec 2014 to Dec 2017
- Other Products40 · Dec 2014 to Dec 2017
- Pp And E Godollo2 · Dec 2016 to Dec 2017
- Teva And Subsidiaries2 · Dec 2016 to Dec 2017
- Godollo2 · Jun 2017 to Sep 2017
- Actavis Eu And Row Product Rights1 · Dec 2017
- Actavis Us Product Rights Revaluation1 · Dec 2017
- Actavis Us Product Rights Termination1 · Dec 2017
- Discontinued Actavis Products1 · Dec 2017
- Discontinued Rimsa Projects1 · Dec 2017
- Discontinued Specialty Products1 · Dec 2017
- Expenses Related To Bendeka1 · Dec 2017
- Expenses Related To Lama Laba1 · Dec 2017
- Identifiable Ipr And D1 · Dec 2017
- Mesoblast1 · Dec 2015
- Pp And E1 · Dec 2017
- Pp And E Japan1 · Dec 2017
- Pp And E Jerusalem1 · Dec 2017
- Pp And E Pr Nj And Canada1 · Dec 2017
- Pp And E Raanana1 · Dec 2017
- Product Rights1 · Dec 2017
- Products Acquired From Actavis1 · Dec 2017
- Revascor1 · Dec 2016
- Teva Takeda Product Rights1 · Dec 2017
- Varioustevamarkets1 · Dec 2016
- Zecuity1 · Dec 2016
Subsegments2 members · 58 facts
- Medis Reporting Units29 · Dec 2022 to Dec 2025
- Tevas Api Reporting Unit29 · Dec 2022 to Dec 2025
Statement geographicalus-gaap:StatementGeographicalAxis11 members · 47 facts
- Other countries11 · Dec 2015 to Dec 2025
- Europe8 · Mar 2017 to Mar 2018
- North America8 · Mar 2017 to Mar 2018
- Croatia3 · Dec 2015 to Dec 2017
- Germany3 · Dec 2015 to Dec 2017
- Hungary3 · Dec 2015 to Dec 2017
- Israel3 · Dec 2015 to Dec 2017
- Japan3 · Dec 2015 to Dec 2017
- IL2 · Mar 2018
- United states2 · Dec 2015 to Dec 2016
- IN1 · Mar 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary242 claims from 9 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary279 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes16 claims from 1 reports · Dec 2025
- Risk factors83 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · Apr 2026 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 29, 2026
- FY2026 Q1Apr 29, 2026
Executive media
10 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- TV interviews6 · Nov 2021 to Jul 2025
- Other appearances3 · Feb 2021 to May 2023
- Podcasts1 · Jul 2024
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.